Cannabis Science Receives Initial Batch of Nebulizers for CBIS MDI Rescue Inhalers Targeting Asthma/COPD; Prepares Packaging & Distribution
IRVINE, CA--(Marketwired - Sep 6, 2016) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is excited to announce they have received their initial batch of nebulizers for their cannabinoid-based MDI rescue inhalers, which targets asthma/COPD for legal self-medicating patients. Previous third-party studies using cannabis-based treatments for asthma/COPD have shown positive results with fewer side effects, and that has spurred the company to move to market as quickly as possible to capitalize on the infancy of the market.
In addition to select dispensaries in California, the company will be testing the initial batch out with 20-25 legal self-medicating candidates suffering from asthma/COPD and other respiratory ailments in the State of California. The observational study will allow the company to confirm observation efficacy, develop additional marketing materials, and improve product design while building a wider spread release.
"We are upgrading the website now to accept patient data and tracking. We are excited to start with patients in the Los Angeles area who have previously had limited access to cannabis-based asthma/COPD targeting treatments," said Director, President, CEO & Co-Founder, Raymond C. Dabney, "We believe patients in legal states will benefit greatly from the addition of an effective, alternative treatment with seemingly less prevalent side effects."
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.